You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Dual View Endoscopy for Colonoscopy

    SBC: OMNISCIENT IMAGING INC            Topic: 102

    AbstractAn estimatedmillion colonoscopies are performed annually in the US at a cost of about $Bhowever current colonoscopes with forward vision fail to detectof precancerous polypsOverof the missed polyps are located on or behind numerous folds in the colon where they are hidden from the sight of a forward view colonoscopeIn this research proposalwe propose to complete our development of an imagi ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. A Method to Increase Buprenorphine Treatment Capacity and Effectiveness

    SBC: CBT4CBT LLC            Topic: R42

    The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioiddependent patientsOvermillion people in the US are addicted to opiatesProviding effective agonist therapymethadone or buprenorphinecoupled with behavioral counseling greatly improves outcomesreduces morbidityand reduces societal costsMethadone maintenance treatment has been limited due to complex sta ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Optimizing Direct Delivery of Nucleic Acid Therapeutics

    SBC: FHC, INC.            Topic: NIMH

    Project Summary While nucleic acid therapeutics have shown promise in rodent and nonhuman primate models of CNS diseasesall double blind clinical trials to date have failedOne likely explanation for this failure is poor therapeutic distribution in targeted brain regionsFor examplepost mortem studies of patients with Parkinsonandapos s Disease receiving intraparenchymal injections of AAV NTN demons ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. DNA Quadruplex Control of hTERT Transcription: A New Therapy for Taxotere Resistant Prostate Cancer

    SBC: Reglagene, LLC            Topic: 102

    PROJECT SUMMARYTelomerase maintains telomere length and prevents cellular senescenceIt is upregulated inof cancerssuppressed in most non cancer tissuesand is a primary driver of tumor cell immortalityNo clinical agent acting on telomerase has been approved for human useA hurdle for approaches that directly inhibit the action of telomerase is that therapeutic effect is observed only after many popu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML

    SBC: SYNACTIX PHARMACEUTICALS, INC.            Topic: 102

    ABSTRACTThe Aurora Kinase FamilyAKFcomprises heavily pursued therapeutic targets for cancer because of their intimate involvement in cell division and tumor progressionNumerous therapeutic campaigns have been initiated against the AKFwith promising clinical successes emanating from strategies targeting either Aurora A or Aurora BHoweverthe US Food and Drug Administration has yet to approve a cance ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Treatment for Acetominophen-Induced Liver Injury

    SBC: MITOTHERAPEUTIX, LLC            Topic: 300

    Abstract The Specific Aim of this Phase I STTR proposal is to test the feasibility of blocking MCJalso called DnaJCto overcome acute acetaminophen liver toxicityAcetaminophen or APAPfrom acetyl paraaminophenolis a common drug used to address pain and feverIn the US aloneaboutpatients per year are admitted to intensive care units with APAP induced liver injury and close toof these patients undergo ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government